Anorexia-cachexia syndrome in pancreatic cancer: Recent advances and new pharmacological approach

Advances in Medical Sciences

Volumn 59, Issue 1, 2014, Pages 1-6

  Ronga, Ilaria ^a   Gallucci, Fernando ^a   Riccardi, Ferdinando ^a   Uomo, Generoso ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

Anorexia; Cachexia; Corticosteroids; Megestrol; Pancreatic adenocarcinoma; Thalidomide

Indexed keywords

ADENOSINE TRIPHOSPHATE; CANNABINOID; CENTRAL STIMULANT AGENT; CORTICOSTEROID; CYPROHEPTADINE; DRONABINOL; GESTAGEN; ICOSAPENTAENOIC ACID; INSULIN; MEDROXYPROGESTERONE; MEGESTROL ACETATE; MELATONIN; NANDROLONE DECANOATE; NONSTEROID ANTIINFLAMMATORY AGENT; OXANDROLONE; PENTOXIFYLLINE; THALIDOMIDE;

ANOREXIA; CACHEXIA; CANCER ANOREXIA CACHEXIA SYNDROME; CANCER GROWTH; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIPID METABOLISM; MALNUTRITION; PANCREAS CANCER; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN METABOLISM; QUALITY OF LIFE; REVIEW; WEIGHT REDUCTION; COMPLICATION; PANCREAS TUMOR;

ANOREXIA; CACHEXIA; HUMANS; PANCREATIC NEOPLASMS; QUALITY OF LIFE;

EID: 84907680326     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.1016/j.advms.2013.11.001     Document Type: Review

References (64)

1. A. Skorokhod, J. Bachmann, N.A. Giese, M.E. Martignoni, and H. Krakowski-Roosen Real-imaging cDNA-AFLP transcript profiling of pancreatic cancer patients: Egr-1 as a potential key regulator of muscle cachexia BMC Cancer 12 2012 265 269
2. S.D. Stan, S.V. Singh, and R.E. Brand Chemoprevention strategies for pancreatic cancer Nat Rev Gatroenteral Hepatol 7 2010 347 356
3. T. Hackert, M.W. Büchler, and J. Werner Surgical options in the management of pancreatic cancer Minerva Chir 64 2009 465 476
4. M.G. House, and M.A. Choti Palliative therapy for pancreatic/biliary cancer Surg Oncol Clin N Am 13 2004 491 503
5. P.J. Kneuertz, S.C. Cunningham, J.L. Cameron, S. Torrez, N. Tapazoglou, and J.M. Herman Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience J Gastrointest Surg 15 2011 1917 1927
6. J. Bachmann, K. Ketterer, C. Marsch, K. Fechtner, H. Krakowski-Roosen, and M.W. Büchler Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function BMC Cancer 9 2009 255 259
7. T. Okusaka, S. Okada, H. Ishii, M. Ikeda, H. Kosakamoto, and M. Yoshimori Prognosis of advanced pancreatic cancer patients with reference to calorie intake Nutr Cancer 32 1998 55 58
8. S. Fazal, and M.W. Saif Supportive and Palliative care of Pancreatic cancer JOP 10 2007 240 253
9. X. Zhou, J.L. Wang, J. Lu, Y. Song, K.S. Kwak, and Q. Jiao Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival Cell 142 2010 531 543
10. G. Uomo, F. Gallucci, and P.G. Rabitti Anorexia-Cachexia Syndrome in pancreatic cancer: recent development in research and management JOP 7 2006 157 162
11. A. Inui Cancer anorexia-cachexia syndrome: current issues in research and management CA Cancer J Clin 52 2002 72 91
12. M.J. Tisdale Cachexia in cancer patients Nat Rev Cancer 2 2002 862 871
13. K.A. Nelson, D. Walsh, and F.A. Sheehan The cancer anorexia-cachexia syndrome J Clin Oncol 12 1994 213 225
14. S.Y. Kim, G.A. Wie, W.J. Lee, S.J. Park, and S.M. Woo Changes in dietary intake, body weight, nutritional status, and metabolic rate in a pancreatic cancer patient Clin Nutr Res 2 2013 154 158
15. N. Johns, N.A. Stephens, and K.C. Fearon Muscle wasting in cancer Int J Biochem Cell Biol 45 2013 2215 2229
16. K.C. Fearon, A.C. Voss, D.S. Hustead Cancer Cachexia Study Group Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis Am J Clin Nutr 83 2006 1345 1350
17. M.J. Tisdale Mechanism of cancer cachexia Physiol Rev 89 2009 381 410
18. N. MacDonald, A.M. Easson, V.C. Mazurak, G.P. Dunn, and V.E. Baracos Understanding and managing cancer cachexia J Am Coll Surg 197 2003 143 161
19. W.J. Evans, J.E. Morley, J. Argilés, C. Bales, V. Baracos, and D. Guttridge Cachexia: a new definition Clin Nutr 27 2008 793 799
20. G. Mantovani, C. Madeddu, and A. Macciò Cachexia and oxidative stress in cancer: an innovative therapeutic management Curr Pharm Des 18 2012 4813 4818
21. C.L. Donohoe, A.M. Ryan, and J.V. Reynolds Cancer cachexia: mechanisms and clinical implications Gastroenterol Res Pract 2011 2011 601434
22. J. Ockenga, and L. Valentini Review article: anorexia and cachexia in gastrointestinal cancer Aliment Pharmacol Ther 22 2005 583 594
23. E. Elamin Dietary and pharmacological management of severe catabolic conditions Am J Med Sci 342 2011 513 518
24. E.J. Ramos, S. Suzuki, D. Marks, A. Inui, A. Asakawa, and M.M. Meguid Cancer anorexia-cachexia syndrome: cytokines and neuropeptides Curr Opin Clin Nutr Metab Care 7 2004 427 434
25. A. Inui Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 59 1999 4493 4501
26. N.M. Ellison, E. Chevlen, C.D. Still, and S. Dubagunta Supportive care for patients with pancreatic adenocarcinoma: symptom control and nutrition Hematol Oncol Clin North Am 16 2002 105 121
27. S.T. Russell, K. Hirai, and M.J. Tisdale Role of β-3 adrenergic receptors in the action of tumour lipid mobilizing factor Br J Cancer 86 2002 424 428
28. S.J. Wigmore, P.T. Todorov, M.D. Barber, J.A. Ross, M.J. Tisdale, and K.C. Fearon Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor Br J Surg 87 2000 53 58
29. M. Löhr, and H. Friess Pancreatic cancer 2005 Uni Med-Verlag Bremen, Germany
30. F. Penna, G. Bonelli, F.M. Baccino, and P. Costelli Mechanism-based therapeutic approaches to cachexia Vitam Horm 92 2013 271 299
31. F.G. El-Kamar, M.L. Grossbard, and P.S. Kozuch Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care Oncologist 8 2003 18 34
32. A. Pascual López, M. Roqué i Figuls, G. Urrútia Cuchi, E.G. Berenstein, B. Almenar Pasies, and M. Balcells Alegre Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome J Pain Symptom Manage 27 2004 360 369
33. V. Ruiz Garcia, E. López-Briz, R. Carbonell Sanchis, J.L. Gonzalvez Perales, and S. Bort-Marti Megestrol acetate for treatment of anorexia cachexia syndrome CDS Rev 2013
34. H. Suzuki, A. Asakawa, H. Amitani, N. Nakamura, and A. Inui Cancer cachexia - pathophysiology and management J Gastroenterol 48 2013 574 594
35. J.R. Nicholson, K.G. Hofbauer, S.D. Anker, and A. Inui John M. Appetite stimulants. Pharmacotherapy of cachexia 2006 CRC Press Boca Raton 291 302 [chapter 16]
36. A. Tuca, P. Jimenez-Fonseca, and P. Gascón Clinical evaluation and optimal management of cancer cachexia Crit Rev Oncol Hematol 2013
37. C.L. Loprinzi, J.W. Kugler, J.A. Sloan, J.A. Mailliard, J.E. Krook, and M.B. Wilwerding Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia J Clin Oncol 17 1999 3299 3306
38. A. Jatoi Pharmacologic therapy for the cancer cachexia/weight loss syndrome: a data-driven, practical approach J Support Oncol 4 2006 499 502
39. G. Mantovani, A. Maccio, E. Massa, and C. Madeddu Managing cancer-related anorexia/cachexia Drugs 61 2001 499 514
40. C.G. Kardinal, C.L. Loprinzi, D.J. Schaid, A.C. Hass, A.M. Dose, and L.M. Athmann A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia Cancer 65 1990 2657 2662
41. W.B. Daviss, and J. Scott A chart review of cyproheptadine for stimulant-induced weight loss J Child Adolesc Psychopharmacol 14 2004 65 73
42. A.D. Genazzani, C. Strucchi, B. Malavasi, F. Tortolani, F. Vecchi, and S. Luisi Effects of cyproheptadine clorhydrate, a serotonin receptor antagonist, on endocrine parameters in weight-loss related amenorrhea Gynecol Endocrinol 15 2001 279 285
43. M.D. Barber, J.A. Ross, A.C. Voss, M.J. Tisdale, and K.C. Fearon The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer Br J Cancer 81 1999 80 86
44. S.J. Wigmore, M.D. Barber, J.A. Ross, M.J. Tisdale, and K.C. Fearon Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer Nutr Cancer 36 2000 177 184
45. A. Dewey, C. Baughan, T. Dean, B. Higgins, and I. Johnson Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia CDS Rev 2007
46. J.N. Gordon, T.M. Trebble, R.D. Ellis, H.D. Duncan, T. Johns, and P.M. Goggin Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial Gut 54 2005 540 545
47. S.C. Sanchetee Thalidomide versus thalidomide with olanzapine and megastrol acetate in treatment of cachexia in gastrointestinal cancer: a randomized trial ASCO Gastrointestinal Cancers Symposium 2010 No. 209
48. M.D. DeBoer Update on melanocortin interventions for cachexia: progress toward clinical application Nutrition 26 2010 146 151
49. D.L. Marks, N. Ling, and R.D. Cone Role of the central melanocortin system in cachexia Cancer Res 61 2001 1432 1438
50. S. Markison, A.C. Foster, C. Chen, G.B. Brookhart, A. Hesse, and S.R. Hoare The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist Endocrinology 146 2005 2766 2773
51. M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa Ghrelin is a growth-hormone-releasing acylated peptide from stomach Nature 402 1999 656 660
52. A. Inui Ghrelin: an orexigenic and somatotrophic signal from the stomach Nat Rev Neurosci 2 2001 551 560
53. T. Akamizu, and K. Kangawa Ghrelin for cachexia J Cachexia Sarcopenia Muscle 1 2010 169 176
54. E. Gonzalez-Rey, A. Chorny, and M. Delgado Therapeutic action of ghrelin in a mouse model of colitis Gastroenterology 130 2006 1707 1720
55. T. Waseem, M. Duxbury, H. Ito, S.W. Ashley, and M.K. Robinson Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways Surgery 143 2008 334 342
56. V.D. Dixit, E.M. Schaffer, R.S. Pyle, G.D. Collins, S.K. Sakthivel, and R. Palaniappan Ghrelin inhibits leptin- and activation induced proinflammatory cytokine expression by human monocytes and T cells J Clin Invest 114 2004 57 66
57. W.G. Li, D. Gavrila, X. Liu, L. Wang, S. Gunnlaugsson, and L.L. Stoll Ghrelin inhibits proinflammatory responses and nuclear factor-kB activation in human endothelial cells Circulation 109 2004 2221 2226
58. R. Wu, W. Dong, M. Zhou, F. Zhang, C.P. Marini, and T.S. Ravikumar Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats Am J Respir Crit Care Med 176 2007 805 813
59. M.M. Theil, S. Miyake, M. Mizuno, C. Tomi, J.L. Croxford, and H. Hosoda Suppression of experimental autoimmune encephalomyelitis by ghrelin J Immunol 183 2009 2859 2866
60. J. Garcia, R.V. Boccia, C. Graham, K. Kumor, and V. Polvino A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia J Clin Oncol, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 25, no. 18S (June 20 Supplement) 2007 9133
61. J.M. Garcia, J. Friend, and S. Allen Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study Support Care Cancer 21 2013 129 137
62. E. Topkan, A.A. Yavuz, and O. Ozyilkan Cancer cachexia: pathophysiologic aspects and treatment options Asian Pac J Cancer Prev 8 2007 445 451
63. G. Mantovani, A. Macciò, C. Madeddu, R. Serpe, E. Massa, and M. Dessì Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia Oncologist 15 2010 200 211
64. E. Tazi, and H. Errihani Treatment of cachexia in oncology Indian J Palliat Care 16 2010 129 137